Schizophrenia [clinicaltrials_resource:79ce9bd96a3184b1ee7c700aa2927e67]
clinicaltrials:NCT00000371clinicaltrials:NCT00000372Treatment for First-Episode Schizophrenia [clinicaltrials:NCT00000374]Self-Management Therapy for Youth With Schizophrenia [clinicaltrials:NCT00000387]Neuropsychological Evaluation of Psychiatric and Neurological Patients [clinicaltrials:NCT00001192]Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia [clinicaltrials:NCT00001198]Inpatient Evaluation of Adults With Schizophrenia [clinicaltrials:NCT00001247]Studies of Frontal Lobe Brain Functioning in Schizophrenia [clinicaltrials:NCT00001258]Brain Tissue Collection for Neuropathological Studies [clinicaltrials:NCT00001260]Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients [clinicaltrials:NCT00001320]Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia [clinicaltrials:NCT00001323]Genetic Study of Schizophrenia [clinicaltrials:NCT00001486]Genetic Aspects of Neurologic and Psychiatric Disorders [clinicaltrials:NCT00001544]clinicaltrials:NCT00001656Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) [clinicaltrials:NCT00001768]I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers [clinicaltrials:NCT00001771]Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia [clinicaltrials:NCT00001920]Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings [clinicaltrials:NCT00001921]clinicaltrials:NCT00004980Glycine to Treat Psychotic Disorders in Children [clinicaltrials:NCT00005658]Glucose Regulation During Risperidone and Olanzapine Treatment [clinicaltrials:NCT00006195]Molecular Genetics of Schizophrenia [clinicaltrials:NCT00006418]To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia [clinicaltrials:NCT00007774]Improving Health Services for Veterans With Schizophrenia [clinicaltrials:NCT00012961]A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines [clinicaltrials:NCT00013000]CATIE- Schizophrenia Trial [clinicaltrials:NCT00014001]Cognitive - Behavioral Therapy [clinicaltrials:NCT00018629]Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder [clinicaltrials:NCT00018642]Antipsychotic Response in Schizophrenia [clinicaltrials:NCT00018668]Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome [clinicaltrials:NCT00018837]5HT3 Antagonism and Auditory Gating in Schizophrenia [clinicaltrials:NCT00018850]The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia [clinicaltrials:NCT00034749]A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. [clinicaltrials:NCT00034775]Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia [clinicaltrials:NCT00034801]CAFE Comparison of Atypicals in First Episode of Psychosis [clinicaltrials:NCT00034892]A Comparison of Seroquel vs. Risperidone in Schizophrenia [clinicaltrials:NCT00034905]Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia [clinicaltrials:NCT00036088]Study of Alternate Formulation of Aripiprazole in Agitated Patients With Schizophrenic Disorders [clinicaltrials:NCT00036127]Broad Effectiveness: Study With Aripiprazole [clinicaltrials:NCT00036361]Transcranial Magnetic Stimulation (TMS) Treatment for Patients With Persistent Auditory Hallucinations [clinicaltrials:NCT00042159]
condition [clinicaltrials_vocabulary:condition]
clinicaltrials:NCT00000371clinicaltrials:NCT00000372Treatment for First-Episode Schizophrenia [clinicaltrials:NCT00000374]Self-Management Therapy for Youth With Schizophrenia [clinicaltrials:NCT00000387]Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia [clinicaltrials:NCT00001198]Inpatient Evaluation of Adults With Schizophrenia [clinicaltrials:NCT00001247]Studies of Frontal Lobe Brain Functioning in Schizophrenia [clinicaltrials:NCT00001258]Brain Tissue Collection for Neuropathological Studies [clinicaltrials:NCT00001260]Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients [clinicaltrials:NCT00001320]Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia [clinicaltrials:NCT00001323]Genetic Study of Schizophrenia [clinicaltrials:NCT00001486]Genetic Aspects of Neurologic and Psychiatric Disorders [clinicaltrials:NCT00001544]clinicaltrials:NCT00001656Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) [clinicaltrials:NCT00001768]I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers [clinicaltrials:NCT00001771]Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia [clinicaltrials:NCT00001920]Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings [clinicaltrials:NCT00001921]clinicaltrials:NCT00004980Glycine to Treat Psychotic Disorders in Children [clinicaltrials:NCT00005658]Molecular Genetics of Schizophrenia [clinicaltrials:NCT00006418]To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia [clinicaltrials:NCT00007774]Improving Health Services for Veterans With Schizophrenia [clinicaltrials:NCT00012961]A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines [clinicaltrials:NCT00013000]CATIE- Schizophrenia Trial [clinicaltrials:NCT00014001]Cognitive - Behavioral Therapy [clinicaltrials:NCT00018629]Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder [clinicaltrials:NCT00018642]Antipsychotic Response in Schizophrenia [clinicaltrials:NCT00018668]Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome [clinicaltrials:NCT00018837]5HT3 Antagonism and Auditory Gating in Schizophrenia [clinicaltrials:NCT00018850]The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia [clinicaltrials:NCT00034749]A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. [clinicaltrials:NCT00034775]Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia [clinicaltrials:NCT00034801]A Comparison of Seroquel vs. Risperidone in Schizophrenia [clinicaltrials:NCT00034905]Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia [clinicaltrials:NCT00036088]Electroconvulsive Therapy in Clozapine Refractory Schizophrenia [clinicaltrials:NCT00042224]clinicaltrials:NCT00044005clinicaltrials:NCT00044044clinicaltrials:NCT00044083The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder [clinicaltrials:NCT00044187]clinicaltrials:NCT00044655
condition browse [clinicaltrials_vocabulary:condition-browse]
clinicaltrials:NCT00000371clinicaltrials:NCT00000372Treatment for First-Episode Schizophrenia [clinicaltrials:NCT00000374]Self-Management Therapy for Youth With Schizophrenia [clinicaltrials:NCT00000387]Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia [clinicaltrials:NCT00001198]Inpatient Evaluation of Adults With Schizophrenia [clinicaltrials:NCT00001247]Studies of Frontal Lobe Brain Functioning in Schizophrenia [clinicaltrials:NCT00001258]Brain Tissue Collection for Neuropathological Studies [clinicaltrials:NCT00001260]Neuroimaging of Dopamine Metabolism in Normal and Psychiatric Patients [clinicaltrials:NCT00001320]Neuropsychiatric Evaluation of Healthy Volunteers and Adults With Schizophrenia [clinicaltrials:NCT00001323]Genetic Study of Schizophrenia [clinicaltrials:NCT00001486]Genetic Aspects of Neurologic and Psychiatric Disorders [clinicaltrials:NCT00001544]clinicaltrials:NCT00001656Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg) [clinicaltrials:NCT00001768]I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers [clinicaltrials:NCT00001771]Eye Blink Response in Healthy Volunteers and Adults With Schizophrenia [clinicaltrials:NCT00001920]Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings [clinicaltrials:NCT00001921]clinicaltrials:NCT00004980Glycine to Treat Psychotic Disorders in Children [clinicaltrials:NCT00005658]Molecular Genetics of Schizophrenia [clinicaltrials:NCT00006418]To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia [clinicaltrials:NCT00007774]Improving Health Services for Veterans With Schizophrenia [clinicaltrials:NCT00012961]A Multi-Site Study of Strategies for Implementing Schizophrenia Guidelines [clinicaltrials:NCT00013000]CATIE- Schizophrenia Trial [clinicaltrials:NCT00014001]Cognitive - Behavioral Therapy [clinicaltrials:NCT00018629]Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder [clinicaltrials:NCT00018642]Antipsychotic Response in Schizophrenia [clinicaltrials:NCT00018668]Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome [clinicaltrials:NCT00018837]5HT3 Antagonism and Auditory Gating in Schizophrenia [clinicaltrials:NCT00018850]The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia [clinicaltrials:NCT00034749]A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia. [clinicaltrials:NCT00034775]Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia [clinicaltrials:NCT00034801]A Comparison of Seroquel vs. Risperidone in Schizophrenia [clinicaltrials:NCT00034905]Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia [clinicaltrials:NCT00036088]Electroconvulsive Therapy in Clozapine Refractory Schizophrenia [clinicaltrials:NCT00042224]clinicaltrials:NCT00044005clinicaltrials:NCT00044044clinicaltrials:NCT00044083The Assessment of a Weight-Gain Agent for the Treatment of Olanzapine-Associated Anti-Obesity Agent in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder [clinicaltrials:NCT00044187]clinicaltrials:NCT00044655
condition mesh [clinicaltrials_vocabulary:condition-mesh]
eligibility for clinicaltrials:NCT00155636 [clinicaltrials_resource:1f2fd32b4acc6ec7a0b647c852e443cd]eligibility for clinicaltrials:NCT00100165 [clinicaltrials_resource:40745169026d0e236323f60d7ce7bee2]eligibility for clinicaltrials:NCT00173069 [clinicaltrials_resource:42daff3e3e12f7a405c61bb4a87b87ab]eligibility for clinicaltrials:NCT00155519 [clinicaltrials_resource:611d74fa5a931cc62e1f53e0b4d15a4f]eligibility for clinicaltrials:NCT01409590 [clinicaltrials_resource:6bfd45aa359905490892231a856ec84b]eligibility for clinicaltrials:NCT01411566 [clinicaltrials_resource:6d425873a680b534cf3a56ed681569e2]eligibility for clinicaltrials:NCT01378403 [clinicaltrials_resource:73d8548f2d9937e882cf3b730f5541c5]eligibility for clinicaltrials:NCT00186771 [clinicaltrials_resource:770127e4be3fb7fe08d9f1755ffb9bd0]eligibility for clinicaltrials:NCT00155207 [clinicaltrials_resource:9fb7ad9d10537973fd60ce52b1367e7b]eligibility for clinicaltrials:NCT00657631 [clinicaltrials_resource:ab5f75bd176475e2126072ca7353d24b]eligibility for clinicaltrials:NCT00155701 [clinicaltrials_resource:b2ec94eec52fb666afe9d9f210e131a5]eligibility for clinicaltrials:NCT01903707 [clinicaltrials_resource:c31de67c3c71b056e6a00b54acc659c0]eligibility for clinicaltrials:NCT00481026 [clinicaltrials_resource:d6216058c93b472ec4a3fd20fabfb69f]eligibility for clinicaltrials:NCT01077687 [clinicaltrials_resource:e61d789831a9fb495677fa03d60a2dd9]
exclusion criteria [clinicaltrials_vocabulary:exclusion-criteria]
eligibility for clinicaltrials:NCT00423033 [clinicaltrials_resource:0f1d731e72d2d7292fb70c716e35fd5f]eligibility for clinicaltrials:NCT00155636 [clinicaltrials_resource:1f2fd32b4acc6ec7a0b647c852e443cd]eligibility for clinicaltrials:NCT00100165 [clinicaltrials_resource:40745169026d0e236323f60d7ce7bee2]eligibility for clinicaltrials:NCT00173069 [clinicaltrials_resource:42daff3e3e12f7a405c61bb4a87b87ab]eligibility for clinicaltrials:NCT01164059 [clinicaltrials_resource:51a586af1886781cea812a89673d6bfa]eligibility for clinicaltrials:NCT00155688 [clinicaltrials_resource:5cb0b8f8ca625c66b450d2b7f81e81c1]eligibility for clinicaltrials:NCT00155519 [clinicaltrials_resource:611d74fa5a931cc62e1f53e0b4d15a4f]eligibility for clinicaltrials:NCT01409590 [clinicaltrials_resource:6bfd45aa359905490892231a856ec84b]eligibility for clinicaltrials:NCT01411566 [clinicaltrials_resource:6d425873a680b534cf3a56ed681569e2]eligibility for clinicaltrials:NCT01378403 [clinicaltrials_resource:73d8548f2d9937e882cf3b730f5541c5]eligibility for clinicaltrials:NCT00186771 [clinicaltrials_resource:770127e4be3fb7fe08d9f1755ffb9bd0]eligibility for clinicaltrials:NCT00155207 [clinicaltrials_resource:9fb7ad9d10537973fd60ce52b1367e7b]eligibility for clinicaltrials:NCT00657631 [clinicaltrials_resource:ab5f75bd176475e2126072ca7353d24b]eligibility for clinicaltrials:NCT00155701 [clinicaltrials_resource:b2ec94eec52fb666afe9d9f210e131a5]eligibility for clinicaltrials:NCT01903707 [clinicaltrials_resource:c31de67c3c71b056e6a00b54acc659c0]eligibility for clinicaltrials:NCT00481026 [clinicaltrials_resource:d6216058c93b472ec4a3fd20fabfb69f]eligibility for clinicaltrials:NCT01077687 [clinicaltrials_resource:e61d789831a9fb495677fa03d60a2dd9]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Schizophrenia [clinicaltrials_resource:79ce9bd96a3184b1ee7c700aa2927e67]
Bio2RDF identifier
79ce9bd96a3184b1ee7c700aa2927e67
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:79ce9bd96a3184b1ee7c700aa2927e67
identifier
clinicaltrials_resource:79ce9bd96a3184b1ee7c700aa2927e67
title
Schizophrenia
@en
type
label
Schizophrenia [clinicaltrials_resource:79ce9bd96a3184b1ee7c700aa2927e67]
@en
Schizophrenia